Develops and markets pharmaceutical products for various therapeutic areas. Offers in-vitro diagnostic tests for disease diagnosis. Now — the numbers.
This is an established company with proven profits.
No real growth.
The gap is $21.7B. In times of high interest rates, a gap like that can squeeze a company.
The market pays 21.3× for every dollar of annual profit — around what a business like this usually costs.
Analysts' average target sits 19% above today's price.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
The stock trades below its recent peak — about 13% off the top. A pullback, not a collapse.
The net profit margin is 20% — still a thick cushion, though costs have been eating into it lately.
It pays out $1.55 per share each year — regular cash for whoever holds the stock.
Over the last 4 years, sales grew only 0% a year on average. At this size, speeding back up is not easy.
The price action doesn’t yet back an upward turn. Council score: 3/10.
Against everything we grade, RHHBY lands somewhere in the middle. The grade moves as the numbers move.
The takeaway: RHHBY is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.
Not covered, because the filings we hold do not carry it: the revenue breakdown.